Cradle

The company positions itself as software rather than a CRO—Cradle runs an internal lab to validate and continuously improve its models—while customers keep their sequences and experimental data private. Cradle’s platform targets multiple protein modalities (including antibodies, enzymes, vaccines, and peptides) and is designed to run across biopharma and industrial bio use cases. In practice, Cradle’s platform combines (1) model-driven generation of candidate protein sequences, (2) use of customers’ experimental results to improve subsequent modeling, and (3) lab-verified evaluation of designs—so that teams can iterate faster than traditional protein engineering cycles. Cradle emphasizes workflow features such as traceability/audit trails and programmatic integration via an API, and it also provides higher-level “guided” campaign structure (so teams can run consistent rounds without having to encode best practices themselves). Strategically, Cradle has moved from stealth to commercialization (with a multi-round funding history culminating in a $73M Series B). The company highlights adoption by large R&D organizations and has announced partnerships/collaborations with major biopharma and industrial players, including Bayer and Lundbeck. As of 2026, Cradle continues to expand product capabilities and scientific/operational capacity (including its emphasis on improving end-to-end throughput and experiment batching).